← Back to Search

FAZA PET Scan for Prostate Cancer

N/A
Recruiting
Research Sponsored by University Health Network, Toronto
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Age ≥ 18 years
Bulky intermediate risk, high risk or metastatic prostate cancer
Must not have
Inability to lie supine for more than 60 minutes
Patients taking the drug disulfiram (Antabuse)
Timeline
Screening 3 weeks
Treatment Varies
Follow Up up to 5 years
Awards & highlights
No Placebo-Only Group

Summary

This trial is testing whether a PET scan can measure low levels of oxygen in prostate cancer, which may affect how well treatment works.

Who is the study for?
This trial is for men over 18 with prostate cancer who plan to receive radiotherapy, hormonal therapy, or other systemic treatments. They must be able to consent and lie supine for an hour. It's not for those over 136 kg, taking disulfiram, or with MRI contraindications (unless the target lesion isn't the prostate).
What is being tested?
The study tests if a PET scan using a tracer called 18F-Fluoroazomycin Arabinoside (18F-FAZA) can detect low oxygen levels in prostate tumors better than current methods. This could influence future treatment strategies.
What are the potential side effects?
While the document doesn't specify side effects of 18F-FAZA, typical PET scan tracers may cause allergic reactions or discomfort at the injection site. The risk of radiation exposure from the scan is also present.

Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below
Select...
I am 18 years old or older.
Select...
My prostate cancer is advanced or has spread to other parts.
Select...
My prostate cancer is of the adenocarcinoma type.
Select...
I plan to undergo radiotherapy with or without hormone therapy.

Exclusion Criteria

You may be eligible for the trial if you check “No” for criteria below:
Select...
I cannot lie on my back for more than an hour.
Select...
I am currently taking disulfiram (Antabuse).

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~up to 5 years
This trial's timeline: 3 weeks for screening, Varies for treatment, and up to 5 years for reporting.

Treatment Details

Awards & Highlights

No Placebo-Only Group
All patients enrolled in this study will receive some form of active treatment.

Trial Design

1Treatment groups
Experimental Treatment
Group I: PET FAZA imagingExperimental Treatment1 Intervention
PET FAZA imaging of tumor hypoxia in patients with prostate cancer

Find a Location

Who is running the clinical trial?

University Health Network, TorontoLead Sponsor
1,531 Previous Clinical Trials
504,302 Total Patients Enrolled
65 Trials studying Prostate Cancer
15,572 Patients Enrolled for Prostate Cancer

Media Library

18F-Fluoroazomycin Arabinoside (18F-FAZA) Clinical Trial Eligibility Overview. Trial Name: NCT01567800 — N/A
Prostate Cancer Research Study Groups: PET FAZA imaging
Prostate Cancer Clinical Trial 2023: 18F-Fluoroazomycin Arabinoside (18F-FAZA) Highlights & Side Effects. Trial Name: NCT01567800 — N/A
18F-Fluoroazomycin Arabinoside (18F-FAZA) 2023 Treatment Timeline for Medical Study. Trial Name: NCT01567800 — N/A
~1 spots leftby Dec 2025
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top